natera™ | Signatera™ Residual disease test (MRD)

Covered by Medicare for patients with stage II-IV ovarian cancer and pan-tumor immunotherapy monitoring

GYNECOLOGIC CANCER

Monitor your patients with gynecologic cancer using tumor-informed ctDNA testing to inform management decisions

Current tools have limited sensitivity and specificity; Signatera™ can help monitor your patients across the treatment continuum.

Post-adjuvant MRD assessment

Identify high risk ovarian cancer patients with molecular residual disease who may benefit from additional treatment

Surveillance/ Maintenance

Detect recurrence ahead of conventional tools with serial ctDNA testing in ovarian cancer patients

IO treatment effectiveness

Monitor ctDNA serially to help determine IO response and clarify indeterminate findings in gynecologic cancer patients

Signatera™ identifies patients at high risk of recurrence and detects recurrence earlier[1]

ctDNA status and relapse-free survival at a single timepoint after definitive treatment



Longitudinal ctDNA status and relapse-free survival



- After completion of adjuvant/definitive therapy, ctDNA was detectable in 23% of patients, all of whom experienced disease progression.[1]
- Longitudinally, ctDNA was detected with 100% sensitivity and specificity[1], while CA-125 had much lower sensitivity (43%) and specificity (78%).[2]

Signatera™ quantifies ctDNA over time to help answer critical questions during immunotherapy treatment

- Is the treatment working?
- Should treatment be changed or escalated?
- Is the cancer actually progressing?
- Is the patient an exceptional responder?

Real endometrial cancer patient case:

Signatera™ ctDNA dynamics help inform early if single agent IO treatment is working or if a change in therapy should be considered.



Early ctDNA dynamics during immunotherapy have been demonstrated to be a strong predictor of treatment benefit across solid tumors and in gynecologic cancers specifically.[3-5]

Ordering Signatera™ for your gynecologic cancer patients:

- Can be run at any time point from diagnosis through recurrence
- Medicare coverage for patients with stage II-IV ovarian cancer to inform treatment decisions in the adjuvant setting and for early detection of recurrence in the surveillance/maintenance settings, as well as monitoring response to immunotherapy in patients with any solid tumor
- One blood draw, one tumor sample, three results: easily add on hereditary cancer and/or tumor genomic profiling to your Signatera™ order

Natera's Oncology Portfolio:

Empower™
Hereditary cancer test

Empower™ for hereditary cancer testing provides clear answers you can act on by analyzing up to 81 genes across 12+ common hereditary cancers. Empower includes more commonly known genes associated with gynecologic cancers (including *BRCA1, BRCA2, BRIP1, RAD51C, RAD51D*, and mismatch repair (MMR) genes for Lynch Syndrome), to help guide therapeutic decisions.

Altera™
Tumor genomic profile

Add on Altera™ Genomic Profiling test which utilizes whole-exome and whole-transcriptome sequencing to identify clinically relevant biomarkers that may help guide treatment selection (including MSI, *BRCA1/2*, HR genes, MMR genes, TMB, *BRAF, RET*, and *NTRK*), with no additional tumor sample needed.

References:

1. Hou et al. Gynecol Oncol. 2022; 167:334-341.
2. Chapman et al. Poster presented at 2021 AACR Annual Meeting.
3. Bratman et al. Nature Cancer. 2020; 1(9):873-881.
4. Recio et al. Poster presented at 2023 SGO Annual Meeting.
5. Backes et al. Poster presented at 2024 SGO Annual Meeting.

Learn more at: natera.com/oncology

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

natera™